According to the analysis in regard to distinct molecular markers, we found that the mRNA expression signature was significantly elevated in IDH wildtype tumors, cases without 1p/19q codeletion, gliomas with homozygous loss of CDKN2A/B and in the EGFR amplification group. The gene discussed is CDKN2A; the disease is glioma.